is there a shortage of tirzepatide FDA says years-long resolved, will give limited leeway to compounders The FDA says the Zepbound
Description
95% CI, 0.57-0.99), ovarian cancer (HR = 0.53

[15] Patients should also seek immediate medical advice if they experience severe, persistent abdominal pain with or without vomiting (which could indicate pancreatitis), or right upper quadrant pain, fever, or jaundice (which could indicate gallbladder disease) both are important warnings in the FDA labeling for semaglutide products

2024 (2) CD002203

Both have been catching up to physicians in prescribing volume, too, as the data indicate

Look at that table as a map, not a verdict

We encourage patients to have thorough discussions with their healthcare providers, addressing: Individual risk factors for vision problems Potential benefits of semaglutide for diabetes management or weight loss Alternative treatment options Monitoring strategies to detect early signs of eye complications For some patients, the benefits of improved blood sugar control or significant weight loss may outweigh the potential vision risks
